Overview
Treating SCLC in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research shows that oncologists may not be offering second-line therapies to patients with SCLC despite good functional status. To help clinicians enhance their diagnostic-therapeutic paradigms for SCLC, this practice guide interweaves education and practical guidance for easy integration of the latest evidence-based strategies into daily clinical processes and workflows.
This activity is intended for medical oncologists, pathologists, advanced practice clinicians, oncology nurses, and other members of the multidisciplinary/multispecialty team who treat patients with SCLC.
SCLC is an aggressive form of lung cancer, characterized by frequent recurrence, treatment resistance, and rapid spread to other organs such as the brain, liver, and bones. The importance of promptly and accurately diagnosing SCLC is underscored by this aggressive nature and the significant impact of early detection on treatment outcomes. Despite being highly responsive to first-line therapy, most individuals with SCLC experience relapse within 2 years and die from systemic metastases.
Until recently, very few options were available for the treatment of SCLC following failure of first-line therapy, typically leading to dismal patient outcomes. However, there has been recent progress in the second-line setting with novel therapeutic options. The escalating complexity and rapid evolution of the SCLC treatment landscape underscore the importance of clinician education.
Until recently, very few options were available for the treatment of SCLC following failure of first-line therapy, typically leading to dismal patient outcomes. However, there has been recent progress in the second-line setting with novel therapeutic options. The escalating complexity and rapid evolution of the SCLC treatment landscape underscore the importance of clinician education.
Upon completion of this activity, learners will be able to:
• Outline evidence-based diagnostic approaches surrounding small-cell lung cancer (SCLC)
• Assess recent safety and efficacy data of new and emerging approaches for the treatment of refractory and relapsed SCLC
• Integrate novel therapeutic agents and approaches into current and evolving SCLC treatment paradigms in the relapsed/refractory setting based on evolving clinical trial findings
• Discuss the pervasive healthcare disparities that disproportionately impact underserved patient populations, particularly in the context of SCLC
• Outline evidence-based diagnostic approaches surrounding small-cell lung cancer (SCLC)
• Assess recent safety and efficacy data of new and emerging approaches for the treatment of refractory and relapsed SCLC
• Integrate novel therapeutic agents and approaches into current and evolving SCLC treatment paradigms in the relapsed/refractory setting based on evolving clinical trial findings
• Discuss the pervasive healthcare disparities that disproportionately impact underserved patient populations, particularly in the context of SCLC
Provided by The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL).
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Firas Badin, MD, MBA
Medical Director for Oncology Research
Internal Medicine
Baptist Health Lexington
Lexington, KY
Medical Director for Oncology Research
Internal Medicine
Baptist Health Lexington
Lexington, KY
Carl Gay, MD
Assistant Professor
Thoracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning adhere to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others, are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
The following financial relationships have been provided:
Firas Badin, MD (Chair )
Consulting Fee – GE | Speakers' Bureau – Amgen |BMS | Jazz | Lilly | Advisor – AbbVie | I-MAB | Merck
Carl Gay, MD (Chair)
Advisor – AstraZeneca US|Catalyst| Daiichi Sankyo, Inc. (Relationship has ended)| G1 Therapeutics (Relationship has ended) |Jazz Pharmaceuticals (Relationship has ended)| Monte Rosa (Relationship has ended)| STCube | Grant or research support – AstraZeneca US| Speakers Bureau – AstraZeneca US (Relationship has ended)| Beigene (Relationship has ended)| Dava Oncology| MJH Healthcare (Relationship has ended)| OncLive (Relationship has ended)
No financial relationships to disclose:
Katlyn Cooper
Danya Garner, PhD, RN, NPD-BC, OCN, CCRN-K
Natasha Mitchner, PhD
Laurie Novoryta, MBA
McKenna Reinhard, MS
Vanessa Senatore
Cicely Simon
Jonathan Sokolowski, PhD
Katlyn Cooper
Danya Garner, PhD, RN, NPD-BC, OCN, CCRN-K
Natasha Mitchner, PhD
Laurie Novoryta, MBA
McKenna Reinhard, MS
Vanessa Senatore
Cicely Simon
Jonathan Sokolowski, PhD
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learner requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: ifinatamab deruxtecan and ABBV-706 (SEZ6 ADC)
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Texas MD Anderson Cancer Center designates this enduring material will award 1.0 Nursing Contact Hours.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
